Congress Materials – American Society of Hematology (ASH 2025)
2025 American Society of Hematology | Dec 6-9 | Orlando, FL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Biomarker Correlates of Clinical Outcomes From a Global Phase 1b Study of JNJ-90014496, CD20/CD19 Bi-Specific Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients With Large B-Cell Lymphoma (LBCL)
Mahipal Suraneni, Da Yin, Dianna Wu, Daksh Thaper, Shajo Kunnath-Velayudhan, Jianmei Wu, Alfredo Perales Puchalt, Melissa Beelen, Julie Larsen, Leen Slaets, Arnob Banerjee, Donne Bennett Caces, Jacqueline Bussolari, Luke Mountjoy, Joanna Rhodes, Jacob Christensen, Martin Hutchings, Matthew Ku, Krish Patel, Vicki Plaks
This document will be available on December 6th 2025
Bleximenib in Combination With Intensive Chemotherapy: A Phase 1b Study in Newly Diagnosed Acute Myeloid Leukemia With KMT2A or NPM1 Alterations
Hartmut Döhner, Andre C. Schuh, Christian Recher, Jenny O’Nions, Ibrahim Aldoss, Ana Alfonso Piérola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo G. Della Porta, Amber D’Souza, James Dugan, Jordi Esteve, Amir T. Fathi, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido Diaz, Olga Salamero, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hutter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sara Garrido Paniagua, Naa Sackey, Tim Sauer, Prathap Nagaraja Shastri, Emma Searle, Natalia Tovar, Danielle Trancucci, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Andrew H. Wei, Christoph Röllig
This document will be available on December 8th 2025
Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind Phase 3 Study (HOVON 181 AML / AMLSG 37-25)
Marc Raaijmakers, Hartmut Döhner, Dimitri Breems, John Byrd, Konstanze Döhner, Jordi Esteve, Bjørn Tore Gjertsen, Patrycja Gradowska, Gerwin Huls, Ain Kaare, Hee-Je Kim, Hitoshi Kiyoi, Mika Kontro, Janusz Krawczyk, Vladimir Lazarevic, Andrea Lenartova, Alice Mims, Jeannine M. Refos, Christoph Röllig, Anika Schrade, Karolina Sikorska, Alexandre Theocharides, Peter J.M. Valk, Adriano Venditti, Jianxiang Wang, Andrew Wei, Agnieszka Wierzbowska, Andrius Žučenka, Lucille Ferrante, Christina Guttke, Angélique Langlois, Christina Loefgren, Kathryn Packman, Prathap Nagaraja Shastri, Natasha Schuier, Meena Thayu, Danielle Trancucci, Bob Löwenberg, Lars Bullinger
This document will be available on December 6th 2025
cAMeLot-2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Bleximenib, Venetoclax, and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
Elias Jabbour, David Sallman, Deborah Briseno-Toomey, Christina Guttke, Xiao-Jun Huang, Richard Dillon, Lucille Ferrante, Takayuki Ikesoe, Angélique Langlois, Christina Loefgren, Boaz Nachmias, Ayelet Nelson, Kathryn Packman, Prathap Nagaraja Shastri, Christian Recher, Gail J Roboz, Natasha Schuier, Meena Thayu, Danielle Trancucci, Athena Zuppa, Christoph Röllig, Andrew Wei
This document will be available on December 7th 2025
Cardiac Risk Factors and Cardiac Events in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis from the Phase 2 Aquarius Study of Daratumumab (DARA) plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd)
Vaishali Sanchorawala, Monique Minnema, Yvonne Efebera, Angela Dispenzieri, Ashutosh Wechalekar, Martha Grogan, Antoine Huart, Michael Rosenzweig, Brandon Blue, Faizi Jamal, Christopher Pericone, Sandra Vasey, Yuping Chen, Matteo Loi, NamPhuong Tran, Efstathios Kastritis
This document will be available on December 7th 2025
Characteristics and Outcomes of Non-Transplanted Newly Diagnosed Multiple Myeloma Patients Treated With Daratumumab, Bortezomib, Lenalidomide, Dexamethasone (DVRd) With Once-Weekly Bortezomib Dosing
Laahn Foster, Xin Yin, Eric Chinaeke, Jinghua He, Vipin Khare, Annelore Cortoos, Rohan Medhekar, Natalia Neparidze
This document will be available on December 6th 2025
Characteristics and Treatment Patterns of Nontransplanted Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in the Frontline Setting
Sikander Ailawadhi, Xin Yin, Eric Chinaeke, Jinghua He, Laura Clark, Annelore Cortoos, a, Rohan Medhekar
This document will be available on December 8th 2025
Ciltacabtagene Autoleucel Out-of-Specification Manufacturing Outcomes Improve With Earlier Lines of Therapy
Robert Bowden, Juan Araque, Gourav Choudhary, Lisa Kallenbach, Victoria Alegria, Octávio Costa, Matthew Perciavalle, James Salmon, Jay Kang, Michael Mondon, Jill Vanak, Daniel Ciccone, Peter Millili, Monica Onorata, Hannelore Van Eeckhoutte, Vicki Plaks, Maximilian Merz
This document will be available on December 6th 2025
Clinical Pharmacology Strategies to Support Dose Optimization of the Recommended Phase 2 Dose Regimen of JNJ-5322, a BCMA×GPRC5D×CD3 Trispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Ashley Nguyen, Jie Zhou, Thomas Prior, Joseph Weidman, Sangmin Lee, Pansy Minnick, Daniel Jonathan, Caroline Hodin, Brandi Hilder, Nikki Daskalakis, Mahesh Samtani, Nahor Haddish-Berhane, Indrajeet Singh
This document will be available on December 7th 2025
Comparative Efficacy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone and Versus Belamaf, Pomalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Previously Treated With 1–3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Christopher Strouse, Surbhi Sidana, Rafael Fonseca, Joaquín Martínez-López, Yael C. Cohen, Binod Dhakal, Murali Janakiram, Suzy Van Sanden, João Mendes, Joris Diels, Seina Lee, Sundar Jagannath
This document will be available on December 7th 2025
Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma: AQUILA Outcomes Based on Mayo 2018/IMWG 2020 Risk Stratification, IMWG 2020 Plus Cytogenetic Criteria, and Age
Peter Voorhees, Meletios Dimopoulos, Yaël Cohen, Fredrik Schjesvold, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Hila Magen, Albert Oriol, Gabor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špička, Anne Mylin, Simon Hallam, Sara Bringhen, Katarina Uttervall, Bartosz Pula, Abdullah Khan, Eva Medvedova, J. Christine Ye, Andrew Cowan, Phillippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, Diego Vieyra, Ashta Raval, Linlin Sha, Liang Li, Els Rousseau, Robyn Dennis, Robin Carson, S. Vincent Rajkumar
This document will be available on December 6th 2025
Discovery of JNJ-87562761, a novel anti-GPRC5D enhanced effector function antibody with multiple mechanisms of action for the treatment of multiple myeloma
Bradley Heidrich, Xiefan Lin-Schmidt, James Testa Jr, Heather Harlin, Jessica Raad, Alexa Marthaler, Katrin Sproesser, Bethany Mattson Cypert, Nicholas Hein, Adam Zwolak, Kavita Raman, William Rittase, Tatiana Perova, Sangmin Lee, Amber D’Souza, M. Phillip DeYoung, Wan Cheung Cheung, Jordan M. Schecter, Ulrike Philippar
This document will be available on December 6th 2025
Dose and BTK Occupancy Relationship in the Prospective Phase 2 TAILOR Study: Exploratory End Point Analysis of the Ibrutinib Monotherapy Cohorts in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Jacqueline C. Barrientos, Michael Doubek, Zsolt Lazar, Andrea Visentin, Javier de la Serna, Luca Laurenti, Alessandro Sanna, Laszlo Retjo, Lucrecia Yanez, Paolo Sportoletti, Carl Gray, Celeste Bremer, Aziz Ouerdani, Nicoline Treijtel, Brendan Hodkinson, John Loffredo, Claire Kavanagh, Sowmya Srikanthan, Ping Xu, Erin Franceschini, Christopher Abbazio, Brooke Patterson, Boo Messahel, Wasiulla Khan, Jan Burger, Lori Parisi, Mark Wildgust, Paolo Ghia, Jeff Sharman
This document will be available on December 7th 2025
Earlier Use of Ciltacabtagene Autoleucel (Cilta-cel) is Associated With Better Immune Fitness and Stronger Immune Effects as Shown by Correlative Analysis of Peripheral Blood and the Bone Marrow Tumor Microenvironment (TME) From the CARTITUDE-4 Study
Samir Parekh, Katherine Li, Niels W.C.J. Van De Donk, Yi Lin, Thomas Martin, Siyu Han, Rocio Montes De Oca, Mahipal Suraneni, Michael Gormley, Brendan Hodkinson, Jinzhou Yuan, Feng Wang, Ashwini Kumar, Da Yin, Denis Smirnov, Jaymala Patel, Nikoletta Lendvai, Deepu Madduri, Jieqing Zhu, Mythili Koneru, Nitin Patel, Dong Geng, Vicki Plaks, Simon Harrison
This document will be available on December 6th 2025
Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Ciltacabtagene Autoleucel: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma
Binod Dhakal, Shinsuke Iida, M Hasib Sidiqi, Elena Zamagni, Sung-Soo Yoon, Natalie Callander, Cyrille Touzeau, Quanlin Li, Agnes Balogh, Ana Slaughter, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Martin Vogel, Nikoletta Lendvai, Tamar Lengil, Mythili Koneru, Nitin Patel, Octavio Costa Filho, Vrinda Mahajan, Joaquín Martínez-López, Kwee Yong, Katja Weisel, Xavier Leleu
This document will be available on December 6th 2025
Effectiveness of Remote Patient Monitoring in Enabling Outpatient Step-Up Dosing for Bispecifics at a Large Academic Cancer Centre in the USA
Sridevi Rajeeve, Matt Wilkes, Nicole Zahradka, Maithili Deshpande, Alice Wang, Issam Hamadeh, Kelly Aliaga, Katie Jones, Kylee Maclachlan, Hamza Hashmi, Carlyn Tan, Malin Hultcrantz, Alexander Lesokhi, Hani Hassoun, Maximilian Merz, Francesco Maura, Parastoo Dahi, Michael Scordo, Heather Landau, Gunjan Shah, Sergio Giralt, Sham Mailankody, Felice Yang, Niodita Gupta-Werner, Tonya LeBlanc, Jessica Fowler, Shuchita Kaila, Saad Usmani, Neha Korde
This document will be available on December 6th 2025
Efficacy and Safety of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: Updated Phase 2 Results From the RedirecTT-1 Study With Extended Follow-Up
Saad Usmani, Shaji Kumar, María-Victoria Mateos, J. Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey Matous, Laura Rosiñol Dachs, Koichi Onodera, Carmela Maffucci, Emma Scott, Christoph Heuck, Jing Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Yaël Cohen
This document will be available on December 7th 2025
Estimating the United States cure-adjusted prevalence of diffuse large B-cell lymphoma (DLBCL): An epidemiological model
Mahmoud Hashim, Tara Beaulieu, Jackie Kwong, Jacqueline Bussolari, Mike Spencer, Maren Gaudig
This document will be available on December 6th 2025
First worldwide real-life data on fixed-duration Ibrutinib+Venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain’s LI+VE observational study
Jose Angel Hernandez Rivas, Ana Muntanola Prat, Esther Sancho Ponce, Angeles Medina, Rafael Lluch-García, Ana C. De Oliveira, Alicia Rodriguez-Fernandez, Juan Alfonso Soler, Maria Jose Terol Castera, Patricia Machado-Machado, Manuel Pérez-Encinas, Rafael Romero-Carmona, Lucrecia Yanez San Segundo, Paloma García-Martín, Clara Mompo, Elena Zubillaga-Marban
This document will be available on December 6th 2025
First-Line Ibrutinib + Venetoclax Shows Benefit Across Genomic Subgroups in Patients With Chronic Lymphocytic Leukemia: Results From Phase 2 CAPTIVATE Study and Phase 3 GLOW Study
Leo Wang-Kit Cheung, Shiquan Wu, Brendan Hodkinson, Constantine S. Tam, William G. Wierda, Paolo Ghia, Anita Szoke, Edith Szafer-Glusman
This document will be available on December 8th 2025
First-Line Treatment in Patients With Transplant-Ineligible, Newly Diagnosed Multiple Myeloma by Age, Frailty, and Comorbidity
Laura Hester, Rupa Makadia, Dmytro Dymshyts, Alana Del Campo, Dongyu Zhang, Thomas Renaud, Helen Pai
This document will be available on December 6th 2025
Impact of previous BCMA exposure: Evidence From Practice Outside of Clinical Trials to Inform Talquetamab Sequencing.
María Jesús Blanchard Rodriguez, Marcos Lorenzo Pérez, Ana Saus Carreres, Mario Arnao Herraiz, Elena Fernández Poveda, Ana Pilar Gonzalez-Rodriguez, Sunil Lakhwani Lakhwani, Juan Luis Reguera Ortega, José María Sánchez Pina, Ana Sánchez Quintana, Miriam González Pardo, María Victoria Mateos Manteca, Paula Rodriguez-Otero
This document will be available on December 6th 2025
Long-Term Progression-Free Survival Benefit With Ciltacabtagene Autoleucel in Standard-Risk Relapsed/Refractory Multiple Myeloma
Luciano Costa, Albert Oriol, Dominik Dytfeld, Salomon Manier, Peter Voorhees, Yi Lin, Myo Htut, Wilfried Roeloffzen, Phoebe Joy Ho, Urvi Shah, Man Zhao, Quanlin Li, Agnes Balogh, Katherine Li, Ana Slaughter, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Huabin Sun, Nikoletta Lendvai, Tamar Lengil, Nitin Patel, Mythili Koneru, Erika Florendo, Octavio Costa, Vrinda Mahajan, Paula Rodríguez-Otero, Christopher Strouse, Keith Stewart, Surbhi Sidana
This document will be available on December 6th 2025
Minimal Residual Disease Dynamics in Post-Transplant Patients With Newly Diagnosed Multiple Myeloma Who Received Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in the AURIGA Study
Alfred Chung, Larry Anderson, Laahn Foster, Chakra Chaulagain, Erin M. Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Douglas Sborov, Kenneth Shain, Rebecca Silbermann, Peter Voorhees, Mitul Gandhi, Maria Krevvata, Mai Ngo, Sharmila Patel, Vipin Khare, Annelore Cortoos, Thomas Lin, Ashraf Badros
This document will be available on December 6th 2025
Optimizing Multiple Myeloma Assessment for Newly Diagnosed Patients Across a Large 33 Hospital Healthcare System: A Mixed Methods Analysis
Bradley Hunter, Heather Black, Jacob Wilkes, Tom Belnap, Daanish Hoda, Prashant Sharma, Kimberly Brunisholz, Andrew Knighton
This document will be available on December 6th 2025
Patient Perspectives and Preferences for Step-Up Dosing and Treatment With Teclistamab and Talquetamab: Insights From a Patient Survey
Jay Hydren, Rachel M Jensen, Jorge Arturo Hurtado Martinez, Jenny M Ahlstrom, Mason Barnes, Caitlin Costello, GurbakhashKaur, Meera Mohan, Francesca Cottini, Douglas Sborov, Shaji Kumar, Noopur Raje, Philippe Moreau, Maithili Deshpande, Niodita Gupta-Werner, Tonya Le Blanc, Jessica Fowler, Rahul Banerjee
This document will be available on December 8th 2025
Phase 1b Study of Bleximenib in Combination With Venetoclax in Acute Myeloid Leukemia With KMT2A or NPM1 Alterations
Jenny O’Nions, Andrew H. Wei, Jordi Esteve, Ibrahim Aldoss, Ana Alfonso Piérola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo G. Della Porta, Hartmut Döhner, Amber D’Souza, James Dugan, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Rachel Kobos, Ana Garrido Diaz, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Danielle Trancucci, Naa Sackey, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hutter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Christian Recher, Christoph Röllig, Olga Salamero, Prathap Nagaraja Shastri, Tim Sauer, Emma Searle, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Uwe Platzbecker, Sylvain Garciaz
This document will be available on December 8th 2025
Prevalence, Incidence, and Outcomes of Multiple Myeloma Patients using Electronic Health Records and Natural Language Processing Insights from the CIMMA study
María-Victoria Mateos, Roberto Trelles, Fernando Escalante Barrigón, Francisco de la Rubia, Natalia Marin Huarte, Angela García Garcia-Porrero, Ana Cáceres Nuñez, Rafael Rios Tamayo, Antonia Sampol Mayol, Eugenio Giménez, Jose Angel Hernandez Rivas, Jaime Perez de Oteyza, Teresa De Soto Alvarez, SRG Savana Research Group, Joaquin Martinez Lopez
This document will be available on December 7th 2025
Quality-Adjusted Survival Analysis of Neurologic Events With Ciltacabtagene Autoleucel vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population
Surbhi Sidana, Leyla Shune, Luciano J Costa, Roberto Mina, Rafal Slowik, Jianming He, João Mendes, Jackie Kwong, Maren Gaudig, Seina Lee, Mukta Sharma, Rakesh Popat, Cyrille Touzeau
This document will be available on December 8th 2025
Real-World Use of Fixed-Duration Ibrutinib+Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Pooled Analysis of REALITY-Worldwide and REALITY-2 Prospective Cohort Studies
Catherine Thieblemont, Emmanuelle Tchernonog, Talha Munir, Oliver Miles, Ingo Schwaner, Ugo Consoli, Vanessa Innao, Anna Mele, Danielle Leão, Adriana Scheliga, Ahmed Absi, Neil Kay, Galia Stemer, Tamar Tadmor, Mark Hoffman, Brian Koffman, Boo Messahel, Sowmya Srikanthan, Erin Franceschini, Christopher Abbazio, Ping Xu, Christoph Tapprich, Claire Kavanagh, Mohamed Fouad, Lori Parisi, Mark Wildgust, Paolo Ghia
This document will be available on December 7th 2025
Real-World Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation (2018–2024) From the HONEUR Network
Blanca Gros Otero, Giselle Lostaunau Costa, Nolen J. Perualila, Kanika Dineshkumar Nahata, Wout Vekemans, Michel Van Speybroeck, Joris Diels
This document will be available on December 8th 2025
Real-World Patient Characteristics, Treatment Patterns, and Outcomes among Relapsed/Refractory Multiple Myeloma Patients Receiving talquetamab-tgvs
Darren Pan, Eric Chinaeke, Yi-hsuan Lisa Liu, Oluwabunmi Emidio, Caleb Paydar, Angele Kotomale, Monica Ahlquist, Bruce Feinberg, Ibrahim Saber, Jessica Fowler, Xinke Zhang
This document will be available on December 6th 2025
Real world use, safety and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the Danish ABCD study.
Astrid Hundebøll Torpe, Jonathan Thorsen, Katrine Fladeland Iversen, Sarah Leeth Farmer, Thomas Lund, Charlotte Hansen, Lene Kongsgaard Nielsen, Nicolai Grønne Dahlager Jørgensen, Maja Vase, Elena Manuela Teodorescu, Gustav Mathiasen, Morten Salomo, Christina Wennerström, Agoston Szabo
This document will be available on December 7th 2025
REVEAL-MM: Retrospective Evaluation of Variables in Early Assessment and Landmark trends in Multiple Myeloma – a US Claims-Based Case-Control Study
Faith Davies, Beth Faiman, Hayley Beer, Anne-Quinn Young, Katie Joyner, Kate Morgan, Stephen Huo, J. Blake Bartlett, Yi Han, Georgia Attfield, Daniel Egbase, Joseph Mikhael
This document will be available on December 7th 2025
Risk of mental health outcomes and peak risk periods post hematologic cancer diagnosis in the United States
Tara Beaulieu, Xiaojian Chen, Joanna Gendreau, Dina Gifkins
This document will be available on December 7th 2025
Safety and Efficacy of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma From Phase 1b of RedirecTT-1: Results With an Extended Median Follow-up of 3 Years
María-Victoria Mateos, Hila Magen, Moshe Gatt, Michael Sebag, Kihyun Kim, Chang-Ki Min, Enrique Ocio, Sung-Soo Yoon, Michael Chu, Paula Rodríguez-Otero, Irit Avivi, Natalia Quijano Cardé, Maria Krevvata, Todd Henninger, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Carmela Maffucci, Emma Scott, Albert Oriol, Daniel Morillo, Yaël Cohen
This document will be available on December 7th 2025
Safety Results From REALiTAL: A Multi-Country Observational Retrospective Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma Outside of Clinical Trials
Rakesh Popat, Katarina Uttervall, Aurore Perrot, Hila Magen, Vitaliy Mykytiv, Carmine Liberatore, Elena Zamagni, Matteo Claudio Da Vià, Elisabetta Antonioli, Markus Hansson, Danielle Greer, Peter Hu, Eric Aeby, Krystof Subrt, Nicholas Francella, Diptendu Santra, Natalia Martin Suñe, K Martin Kortüm
This document will be available on December 7th 2025
Survival Differences in Transplant Ineligible Multiple Myeloma Patients in Japan and Taiwan: Exploring the Potential Influence of Timely and Unrestricted Access to Novel Therapies
Hsin-An Hou, Kenshi Suzuki, David Bin-Cha Wu, Steve Su, Shih-Pei Shen, Chao-Hsiun Tang, DaeYoung Yu, Cathy Kwang-Wei Wu, Saaya Tsutsué, Kittima Wattanakamolkul, Thomas Webb
This document will be available on December 7th 2025
Survival Outcomes of Multiple Myeloma Patients Previously Exposed to BCMA-Targeted Therapies in the HONEUR European Network
Roman Hájek, Jiri Minarik, Martin Stork, Alexandra Jungova, Giselle Lostaunau Costa, Yuwei Wang, Solenn Salaun, Nolen J Perualila, Guillaume Azarias, Markus Rückert
This document will be available on December 7th 2025
Talquetamab Outcomes From Practice Outside of Clinical Trials: The BiTAL Study
María Victoria Mateos Manteca, Marcos Lorenzo Pérez, Ana Saus Carreres, Mario Arnao Herraiz, Elena Fernández Poveda, Ana Pilar Gonzalez-Rodriguez, Sunil Lakhwani Lakhwani, Juan Luis Reguera Ortega, José María Sánchez Pina, Ana Sánchez Quintana, Miriam González Pardo, María Jesús Blanchard Rodriguez, Paula Rodriguez-Otero, on behalf of BiTAL study investigators
This document will be available on December 8th 2025
Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination With Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma: Updated Safety and Efficacy Results From the Phase 1b MonumenTAL-2 Study
Hang Quach, Aurore Perrot, Jeffrey V Matous, Noa Biran, Jesus G Berdeja, Kathleen Dorritie, Janine, Catharina, van Elssen, Cyrille Touzeau, Sébastien Anguille, Gurdeep Parmar, Andrew Spencer, Nicolas Kint, Cyrille Hulin, Kevin Boyd, Rakesh Popat, Wouter Plattel, Attaya Suvannasankha, Ashwini Kumar, Ashwini Rachamalla, Ashley Nguyen, Bhoomika Thakkar, Diana Cortes-Selva, Michela Campagna, Tara Masterson, Veronique Vreys, Paula Barreyro, Gary E Mason, Thomas Renaud, Emma Searle
This document will be available on December 6th 2025
Teclistamab in a Large Cohort of ~100 Asian Patients with Triple-Class Exposed Multiple Myeloma: Experience from Trial and Non-Trial Settings
Tadao Ishida, Jun Ho Yi, Chandramouli Nagarajan, Zhen Cai, Weijun Fu, Shinsuke Iida, Sung Hoon Jung, Yoshiaki Kuroda, Chang-Ki Min, Ting Niu, Aditi S. Manjeri, Dok Hyun Yoon, Kazuko Nishikawa, Xiaohong Wang, Yang Song, Hiroshi Yamazaki, Yusuke Izumi, Jianmin Zhuo, Angeline Zhu, Juan Du
This document will be available on December 8th 2025
TeclistAMY (EMN40): A Phase 2 Trial of Teclistamab in Patients With Previously Treated Light-Chain Amyloidosis
Murielle Roussel, Efstathios Kastritis, Stefan O' Schönland, K. Martin Kortüm, Bertrand Arnulf, Arnaud Jaccard, Sanjay Vara, Margaret Doyle, Jordan M. Schecter, Alexander Carpinteiro, Fiona Kwok, Giovanni Palladini, Monique C. Minnema, Mario Boccadoro, Pieter Sonneveld
This document will be available on December 7th 2025
Updated Analysis of Survival and Treatment Evolution in European Multiple Myeloma Patients (2012–2023) Across 7 Countries From the HONEUR Network
Javier de la Rubia Comos, Roman Hájek, Jiri Minarik, Martin Stork, Alexandra Jungova, Mamta Garg, Yael C. Cohen, Tamir Shragai, Irit Avivi, Svetlana Trestman, Natan Melamed, Marc Maynadié, Adrien Guilloteau, Claudio Cerchione, Alice Andalo, Nicola Gentili, Ilaria Massa, Delia Cangini, Miguel Angel Mayer, Juan Manuel Ramírez-Anguita, Angela Leis, Ceri Bygrave, Hannah Belcher, Blanca Gros Otero, Giselle Lostaunau Costa, Nolen J. Perualila, Wout Vekemans, Michel Van Speybroeck, Joris Diels, Guillaume Azarias, Markus Rückert
This document will be available on December 6th 2025
Updated Efficacy and Safety Results of JNJ-5322, a Novel, Next-Generation, BCMA×GPRC5D×CD3 Trispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Amrita Krishnan, Martin Kaiser, Rakesh Popat, Jeffrey Matous, Alfred Garfall, Gala Vega, Aurore Perrot, Sébastien Anguille, Albert Oriol, Nicolas Kint, Jo Caers, Saad Usmani, Lionel Karlin, Larysa Sanchez, Cindy Varga, Wilfried Roeloffzen, Laura Rosiñol Dachs, Darren Pan, Paula Rodríguez-Otero, María-Victoria Mateos, Tadao Ishida, Kentaro Fukushima, Pansy Minnick, M. Damiette Smit, Nikki Daskalakis, Thomas Prior, Deeksha Vishwamitra, Emily DeSantis, Ashley Nguyen, Brandi Hilder, Joseph Weidman, Caroline Hodin, Daniel Jonathan, Sangmin Lee, Cyrille Touzeau, Hans Lee, Niels W.C.J. Van De Donk, Monique Minnema
This document will be available on December 7th 2025
Utility and Sensitivity of WETT-SA53 to Measure Dysgeusia Associated With Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: Preliminary Data From the TALISMAN Study
Rakesh Popat, Niels WCJ van de Donk, Beth Faiman, Junichiro Yuda, Kihyun Kim, Abel Costa, Alexa Laheij, Richard L Doty, James Omel, Brea Lipe, Larysa Sanchez, Ajai Chari, Alexander Lin, Herve Sroussi, Mariana Fernandez, Kathleen S Gray, Gloria Aguilar, Kasey Bolyard, Jennifer Schultz, Keqin Qi, Diana Cortes-Selva, Jenny Zhang, Chris Heuck, Kelly Hawks, Ken Tian, Monique França, Leo Rasche
This document will be available on December 6th 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
